Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
about
Novel Insights into the Roles of Rho Kinase in CancerApproaches of targeting Rho GTPases in cancer drug discoveryCurrent understanding of conventional outflow dysfunction in glaucomaExciting directions in glaucomaTargeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations.Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost.Latrunculin B Reduces Intraocular Pressure in Human Ocular Hypertension and Primary Open-Angle Glaucoma.Altered mechanobiology of Schlemm's canal endothelial cells in glaucomaIntra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.Targeting Rho-GTPases in immune cell migration and inflammation.TGF-β2-induced invadosomes in human trabecular meshwork cellsRhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork.Glaucoma management: relative value and place in therapy of available drug treatments.Pharmacotherapy of glaucoma.p38 MAP kinase inhibitor suppresses transforming growth factor-β2-induced type 1 collagen production in trabecular meshwork cells.Comparisons of actin filament disruptors and Rho kinase inhibitors as potential antiglaucoma medicationsGalectin-8 promotes cytoskeletal rearrangement in trabecular meshwork cells through activation of Rho signalingDiscovery of Novel ROCK1 Inhibitors via Integrated Virtual Screening Strategy and Bioassays.Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits.Topical treatment of glaucoma: established and emerging pharmacology.MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure.Bioengineered glaucomatous 3D human trabecular meshwork as an in vitro disease model.Novel ocular antihypertensive compounds in clinical trials.Rho-kinase inhibitors offer a new approach in the treatment of glaucoma.Morphological and hydrodynamic correlations with increasing outflow facility by rho-kinase inhibitor Y-27632.Biomechanics of Schlemm's canal endothelium and intraocular pressure reduction.Rho-Associated Kinase Inhibitors: Potential Future Treatments for Glaucoma.Discovery of Rho-kinase inhibitors by docking-based virtual screening.Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma.Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis.Estimating Human Trabecular Meshwork Stiffness by Numerical Modeling and Advanced OCT Imaging.Emerging trabecular outflow drugs.Elevated intraocular pressure induces Rho GTPase mediated contractile signaling in the trabecular meshworkEffect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents.Proteasome Inhibition Increases the Efficiency of Lentiviral Vector-Mediated Transduction of Trabecular Meshwork.ROCK as a therapeutic target for ischemic stroke.Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.The relationship between outflow resistance and trabecular meshwork stiffness in mice.One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
P2860
Q26771368-3483B4AF-5835-47C3-AE6F-FDA78C4A84EEQ26851300-FDED8A7D-E3AA-4FE4-9F37-FD28B44E082BQ26991731-978DCC9D-F5AA-466F-A712-C4F81F766EBDQ28542397-9CB20F6C-FAE2-4B25-A8E5-66A4063B8214Q33665753-5C101CE5-2104-4DFC-99DA-C6C4DE6AE9D2Q33727601-D953FA66-40F5-4A37-BF85-46A74DBD2769Q34181305-3DBBECE6-CA1F-474B-BA7A-8BC61C99FB6CQ34280827-E2B325A9-5BEA-44E3-8800-386329BAB145Q34452693-4B8AF2A2-CC1A-4248-8230-922E6D27E993Q34803380-E6C0DB5E-9205-4014-8367-B318AF14EA39Q34935415-625AF614-1294-4D0D-96DF-61146D7C7E03Q35008515-A4CA92CB-3ADC-4883-93F8-91CB4BD70F23Q35079342-771D13A2-E65B-41F9-8C55-7A08E506E9BCQ35138049-7A67EB2B-C1CA-41D3-BDC3-C16B9C065274Q35583950-1FA8B42F-E835-41CA-A806-E0EBC5299DDCQ36042394-A82EE1C5-4612-445F-99ED-0038BC4A0BCBQ36207409-326A00BB-87BF-45A4-950B-64941142C4A0Q36280727-2BEF0D00-8628-4F3E-BC70-94A8DAE54F99Q36346544-1BC4DC40-541A-48D7-BBA6-93F86D56992BQ36365495-3CB6D5C8-4715-4A77-BFDD-9C69076C988BQ36766565-08A99B32-E476-4E07-9502-268F56A4B441Q36863008-C882C8BB-7F42-435B-A1E5-DDD7CE5EB23FQ37883078-8999AAFC-D0DC-4151-A80B-93C3C287ED46Q38149325-2CEAFACF-57E2-4C8E-8D67-2758FD3A04A8Q38181523-F0BB3044-E8AF-48E9-8EB1-C23DE40C32F1Q38249883-825389A7-5F9A-438E-A46C-75068640A8A7Q39168306-7F7C765E-87DA-48C7-9578-8C55F10B7D07Q39172399-43C50E9B-972C-425F-A96E-0B8A2C954E59Q39206564-F030F317-8219-4ABD-95A2-34BAFD087BE9Q39207696-D5348D7F-AFBD-438A-9B46-06805F2CD834Q41455152-ECF1FB18-BFC2-4611-BF36-23B02CF61DF4Q42286483-9D5CA032-9BE3-4FF7-B372-C3EEE958CB57Q42344015-BCDD6316-E89C-44B4-AB74-42BC127DACD0Q42461840-DAAD2783-36D3-460F-BE2D-7535ABB86D5FQ43991565-F408F81F-472C-442D-9953-937554780822Q47552653-5DBB48AC-E472-440C-A592-255FC67F2C5AQ50066730-E36521E0-92E0-4FBD-B027-BE3BB26B84B0Q50130110-0E0E46FF-7CFF-4C7A-8130-0846FA6D6645Q52593168-3553E428-B53E-45F5-8E20-634F32B7ED2DQ54248457-4BE2786D-1603-4A5B-A0E4-A02450115F20
P2860
Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Ocular hypotensive effect of t ...... ucoma and ocular hypertension.
@en
Ocular hypotensive effect of t ...... ucoma and ocular hypertension.
@nl
type
label
Ocular hypotensive effect of t ...... ucoma and ocular hypertension.
@en
Ocular hypotensive effect of t ...... ucoma and ocular hypertension.
@nl
prefLabel
Ocular hypotensive effect of t ...... ucoma and ocular hypertension.
@en
Ocular hypotensive effect of t ...... ucoma and ocular hypertension.
@nl
P2093
P1476
Ocular hypotensive effect of t ...... ucoma and ocular hypertension.
@en
P2093
AR-12286 Phase 2A Study Group
Casey Kopczynski
Gary D Novack
Robert D Williams
Thomas van Haarlem
P304
P356
10.1016/J.AJO.2011.04.012
P407
P577
2011-07-27T00:00:00Z